Last checked at 4 Aug 2016 11:05
Shield Therapeutics plc
("Shield" or the "Company")
Result of Annual General Meeting
London, UK, 04 August 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that at its Annual General Meeting held today, all resolutions were duly passed.
- Ends -
For further information please contact:
Shield Therapeutics plc | +44 (0)191 511 8507 |
Carl Sterritt, Chief Executive Officer Richard Jones, Chief Financial Officer | |
NOMAD Liberum Capital Limited Christopher Britton Steve Pearce Jamil Miah
| +44 (0)20 3100 2222 |
Financial PR Advisor Consilium Strategic Communications | +44 (0)203 709 5700 shieldtherapeutics@consilium-comms.com |
Mary-Jane Elliott Matthew Neal Lindsey Neville Hendrik Thys |
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The Company has an approved product, Feraccru®, for the treatment of iron deficiency anaemia (IDA). In addition, the Company has a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia), PT20. Shield, based in London and Newcastle, joined AIM in 2016 under the ticker STX. For more information please visit www.shieldtherapeutics.com.